– Bloomberg
Bio-Path Releases Early Cut Data From Mid-Stage Prexigebersen Trial In Acute Myeloid Leukemia
Bio-Path Holdings Inc (NASDAQ: BPTH) reported interim data from Stage 2 of the company's Phase 2 study of prexigebersen in combination with decitabine and venetoclax for